Premium
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end‐stage medullary thyroid carcinoma
Author(s) -
Aller Steven,
Popescu Andrada,
Rao Sudha,
Morgan Elaine,
Gosiengfiao Yasmin
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23032
Subject(s) - medicine , sorafenib , thyroid carcinoma , stage (stratigraphy) , medullary cavity , malignancy , oncology , thyroid cancer , cancer , thyroid , hepatocellular carcinoma , paleontology , biology
Abstract Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC. Pediatr Blood Cancer 2012; 58: 98–100. © 2011 Wiley Periodicals, Inc.